Aethlon Medical Inc (NAS:AEMD)

Q2 2025 Aethlon Medical Inc Earnings Call Transcript

Nov 13, 2024 / 09:30 PM GMT

Release Date Price: $162.44 (+3.18%)

Transcript 10-Q8-K

Key Points

Positve

Aethlon Medical Inc (AEMD) has made significant progress in its oncology trial efforts in Australia, enrolling the first two patients and opening a second hospital for patient enrollment.
The company has successfully reduced its operating expenses by approximately $300,000, primarily through a decrease in professional fees.
Aethlon Medical Inc (AEMD) has received Ethics Committee approval from a hospital in India for a similar oncology trial, expanding its research efforts internationally.
The company holds a cash balance of approximately $6.9 million, providing a solid financial foundation for ongoing research and development.
Aethlon Medical Inc (AEMD) benefits from a 43% tax credit in Australia, significantly reducing the cost of its clinical trials conducted there.

Negative

The company reported a net loss of approximately $2.8 million for the fiscal quarter ended September 30, 2024.
There was an increase of approximately $200,000 in payroll and related expenses, largely due to separation expenses following an executive termination and workforce reduction.
General and administrative expenses increased by $100,000, mainly due to costs related to the ongoing oncology clinical trial.
The company is still awaiting full ethics board approval from a third Australian hospital, which could delay further patient enrollment.
The oncology trials are in early stages, with the first safety data expected only by January, and full data not anticipated until the summer of next year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AEMD.OQ - Aethlon Medical Inc
Q2 2025 Aethlon Medical Inc Earnings Call
Nov 13, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the Athlon Medical fiscal second quarter, 2025 earnings and corporate update. All participants will be in listen-only mode. Should you need assistance? Please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions to ask a question. You may press star then one on your touchtone phone to withdraw your question. Please press star and then two. Please note this event is being recorded. I would now like to turn the conference over to Michael Miller with Rx communications. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.